ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1386

Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active)

Christian Dejaco1, Thomas Mueller2, Omid Zamani, MD3, Ulrike Kurtz, MD4, Stefan Egger, MD5, Johannes Resch Passini, MD6, Anna Totzauer, MD7, Wolfgang Eisterer8, Babak Yazdani-Biuki, MD, Univ.Doc.9, Thomas Schwingenschloegl, MD10, Peter Peichl, MD. Univ.Doc. Msc11, Angelika Kraus12, Gerhard Naerr, PhD13 and Verena Rickert, MD. MBA14, 1Rheumatology and Immunology, Medical University Graz, Graz, Austria, 2Private Office Dr. Thomas Mueller, Graz, Austria, 3Rheuma Zentrum Favoriten, Vienna, Austria, 4Rheuma Praxis Dr. Kurtz, Gleisdorf, Austria, 5Ordination Gesundheitsquadrat, Vienna, Austria, 6Rheumatology Department, Rheuma-Zentrum Wien-Oberlaa GmbH, Vienna, Austria, 7Private Office Dr. Anna Totzauer, Gmuend, Austria, 8Department of Hematology and Internal Oncology, KLINIKUM- KLAGENFURT am WÖRTHERSEE, Klagenfurt, Austria, 9Dr. Schrenk & Dr. Yazdani-Biuki OG - Gruppenpraxis, Fuerstenfeld, Austria, 10Private Office Dr. Thomas Schwingenschloegl, Wiener Neudorf, Austria, 11Private Office Prim. Univ. Doz. Dr. Peter Peichl, MSc, Vienna, Austria, 12Private Office, Private Office Angelika Kraus, Melk, Austria, 13Medical Affairs, Merck Sharp & Dohme GmbH, Vienna, Austria, 14Medical Affairs, Merck Sharp&Dohme GmbH, Vienna, Austria

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Biologics, psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Golimumab has shown clinical efficacy and tolerability within its clinical trial program. No systematic

outcome data regarding patient‐reported outcomes and health economic parameters reflecting real-world use of golimumab in Austria are currently available. Methods:

Go Active is a prospective, non‐interventional, multi‐center study in Austria. The impact of

golimumab therapy on work productivity and activity (WPAI) and quality of life (RAQoL for RA

patients, AsQoL for axSpA patients, PsAQoL for PsA patients) is assessed by using patient-reported outcomes. Patients (target recruitment: n = 220) are followed up to 2 years. In this interim analysis (data cut-off: 03 May 2018) changes in WPAI and QoL from baseline to month 3 are analyzed after recruitment was completed. Results:

At total of 234 patients were enrolled in the study and 189 patients were included in this analysis (81 patients with RA, 56 patients with axSpA, and 52 patients with PsA).

Median age at registration was 52 years (patients with RA: 56 years, patients with axSpA: 40 years, and patients with PsA: 53.5 years). Almost two thirdsof patients were female (81% of patients with RA, 39% patients with axSpA, and 58% of patients with PsA). Most patients were biological-naïve at study entry (78% of all patients, 75% of patients with RA, 79% of patients with axSpA, and 83% of patients with PsA). 38% of patients were not employed (54% of patients with RA, 25% of patients with axSpA and SpA); 14% due to incapacity for work (11% of patients with RA, 21% of patients with axSpA, and 15% of patients with SpA) and 55% due to age-related pension (61% of patients with RA, 21% of patients with axSpA, and 69% of patients with SpA). Most of the patients, who worked for a fee, worked full time.

179 of all patients and 92 of employed patients completed the WPAI questionnaire at baseline and after 3 months. Overall work productivity improved by 35% (40% for patients with RA, and 34% for patients with axSpA and 30% for patients with PsA) and activity impairment by 30% (40% for patients with RA and axSpA, and 20% for patients with PsA; Fig. 1). Quality of life scores improved by 7.5 for patients with RA, by 5 for patients with axSpA, and by 3 for patients with PsA.

Fig. 1: WPAI questionnaire – changes from baseline after 3 months of golimumab treatment

Conclusion:

This interim analysis shows that golimumab is an effective treatment for patients with RA, axSpA and PsA and leads to an improvement of work productivity and daily activities as well as of quality of life already within the first 3 months of treatment. At study entry, most patients were biological-naïve and employed.

 


Disclosure: C. Dejaco, Speaker Bureau < 5000€ received from Sponser MSD, 8; T. Mueller, None; O. Zamani, MD, None; U. Kurtz, MD, None; S. Egger, MD, None; J. Resch Passini, MD, None; A. Totzauer, MD, None; W. Eisterer, None; B. Yazdani-Biuki, MD, Univ.Doc., None; T. Schwingenschloegl, MD, None; P. Peichl, MD. Univ.Doc. Msc, None; A. Kraus, None; G. Naerr, PhD, Employee of Merck Sharp and Dohme, 3; V. Rickert, MD. MBA, Employee of Merck Sharp and Dohme, 3.

To cite this abstract in AMA style:

Dejaco C, Mueller T, Zamani MD O, Kurtz MD U, Egger MD S, Resch Passini MD J, Totzauer MD A, Eisterer W, Yazdani-Biuki MD Univ.Doc. B, Schwingenschloegl MD T, Peichl MD. Univ.Doc. Msc P, Kraus A, Naerr PhD G, Rickert MD. MBA V. Golimumab Improves Work Productivity and Activity As Well As Quality of Life in Patients with Rheumatoid Arthritis (RA), Psoriasis Arthritis (PsA) and Axial Spondyloarthritis (axSpA): Interim Results from a Non-Interventional Study in Austria (Go Active) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/golimumab-improves-work-productivity-and-activity-as-well-as-quality-of-life-in-patients-with-rheumatoid-arthritis-ra-psoriasis-arthritis-psa-and-axial-spondyloarthritis-axspa-interim-results/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/golimumab-improves-work-productivity-and-activity-as-well-as-quality-of-life-in-patients-with-rheumatoid-arthritis-ra-psoriasis-arthritis-psa-and-axial-spondyloarthritis-axspa-interim-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology